IL1B and metabolic disease: Taken together, this evidence suggests that all these pro-inflammatory cytokines are able to modulate CB function via the activation of different signaling pathways and that probably different chronic inflammatory conditions will induce different alterations in TNF-α, IL-1, and IL-6 levels that will differently contribute to CB activation, namely in metabolic diseases.